{
    "clinical_study": {
        "@rank": "141061", 
        "arm_group": [
            {
                "arm_group_label": "Low dose of ABT-450 with ritonavir and ABT-267 for duration 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with genotype 1b or genotype 2"
            }, 
            {
                "arm_group_label": "High dose of ABT-450 with ritonavir and ABT-267 for duration 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with genotype 1b or genotype 2"
            }, 
            {
                "arm_group_label": "Low dose of ABT-450 with ritonavir and ABT-267 for duration 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with genotype 1b"
            }, 
            {
                "arm_group_label": "High dose of ABT-450 with ritonavir and ABT-267 for duration 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with genotype 1b"
            }
        ], 
        "brief_summary": {
            "textblock": "A clinical study to evaluate the safety, tolerability, antiviral activity, and\n      pharmacokinetics of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in treatment experienced\n      Japanese adults with chronic Hepatitis C Virus infection."
        }, 
        "brief_title": "A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis C Virus", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Virus Diseases", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The clinical study is intended to examine the potential impact on safety, pharmacokinetics,\n      antiviral activity, dose ranging and emergence of resistant variants, of two different doses\n      of ABT-450 dosed in combination with ritonavir and ABT-267 for two different treatment\n      periods in Pegylated interferon alpha-2a/Ribavirin treatment experienced, Japanese subjects\n      with hepatitis C virus genotype 1b and genotype 2 infection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously received Pegylated interferon alpha-2a/Ribavirin.\n\n          -  Chronic hepatitis C virus infection.\n\n          -  Plasma hepatitis C virus ribonucleic acid level  greater than 10,000 International\n             Units/milliliter.\n\n          -  Voluntarily sign an informed consent.\n\n        Exclusion Criteria:\n\n          -  History of severe, life-threatening sensitivity to any drug.\n\n          -  Females who are pregnant or plan to become pregnant, or breastfeeding.\n\n          -  Recent history of drug or alcohol abuse.\n\n          -  Positive test result for hepatitis B surface antigen or anti-Human immunodeficiency\n             virus antibodies.\n\n          -  Any current or past clinical evidence of cirrhosis.\n\n          -  Previous use of any investigational or commercially available anti-Hepatitis C virus\n             agent other than Pegylated interferon alpha-2a and Ribavirin, including previous\n             exposure to ABT-450 or ABT-267."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672983", 
            "org_study_id": "M12-536"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low dose of ABT-450 with ritonavir and ABT-267 for duration 1", 
                    "High dose of ABT-450 with ritonavir and ABT-267 for duration 1", 
                    "Low dose of ABT-450 with ritonavir and ABT-267 for duration 2", 
                    "High dose of ABT-450 with ritonavir and ABT-267 for duration 2"
                ], 
                "description": "ABT-450 (tablet) dosed with ritonavir (capsule)", 
                "intervention_name": "ABT-450", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Low dose of ABT-450 with ritonavir and ABT-267 for duration 1", 
                    "High dose of ABT-450 with ritonavir and ABT-267 for duration 1", 
                    "Low dose of ABT-450 with ritonavir and ABT-267 for duration 2", 
                    "High dose of ABT-450 with ritonavir and ABT-267 for duration 2"
                ], 
                "description": "ABT-267 (tablet)", 
                "intervention_name": "ABT-267", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Low dose of ABT-450 with ritonavir and ABT-267 for duration 1", 
                    "High dose of ABT-450 with ritonavir and ABT-267 for duration 1", 
                    "Low dose of ABT-450 with ritonavir and ABT-267 for duration 2", 
                    "High dose of ABT-450 with ritonavir and ABT-267 for duration 2"
                ], 
                "description": "Ritonavir (capsule)", 
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug", 
                "other_name": "Norvir"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ritonavir"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Japanese", 
            "Genotype 1b", 
            "Hepatitis C", 
            "Genotype 2"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chuo", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 74393"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukui-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 76333"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73719"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gifu-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 76335"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hiroshima-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73697"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Inashiki-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73700"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanazawa-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 77253"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawasaki", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73696"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kurume-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73716"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maebashi-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73701"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsuyama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73714"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Musashino-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 75373"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ogaki-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 81633"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73698"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Takamatsu-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73718"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tanabe-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73703"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 76327"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73695"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yufu", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 73717"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2 Study to Evaluate the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection", 
        "overall_official": {
            "affiliation": "AbbVie GK", 
            "last_name": "Shigeki  Hashimoto, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Assess the percentage of all dosed subjects in each treatment arm with sustained virologic response 24 weeks post-dosing (hepatitis C ribonucleic acid less than lower limit of quantitation at 24 weeks after the last dose of study drug).", 
                "safety_issue": "No", 
                "time_frame": "Post Treatment Week 24"
            }, 
            {
                "measure": "Percentage of subjects in each treatment arm with treatment-emergent adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to end of active treatment (up to 24 weeks)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672983"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assess the percentage of all dosed subjects in each treatment arm with a sustained virologic response 12 weeks post-dosing (hepatitis C ribonucleic acid less than lower limit of quantitation 12 weeks after the last dose of study drug).", 
                "safety_issue": "No", 
                "time_frame": "Post Treatment Week 12"
            }, 
            {
                "measure": "Assess the percentage of subjects in each arm with end of treatment response (hepatitis C virus ribonucleic acid less than the lower limit of quantitation).", 
                "safety_issue": "No", 
                "time_frame": "End of Treatment"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}